155229-75-7

Usage

Uses

Used in Pharmaceutical Industry:
(+)-3R,5S-FLUVASTATIN SODIUM SALT is used as an antilipemic agent for the treatment of high cholesterol levels. It helps to reduce the risk of cardiovascular diseases by lowering the levels of low-density lipoprotein (LDL) cholesterol, triglycerides, and apolipoprotein B in the blood.
Additionally, due to its cholesterol-lowering properties, (+)-3R,5S-FLUVASTATIN SODIUM SALT may also be used in the development of drug delivery systems to enhance the bioavailability and therapeutic outcomes of other medications targeting cardiovascular diseases.

Upstream product

• 94061-80-0 fluvastatin sodium 
• 129332-29-2 R*,S*-(E)-(+/-)-3,5-dihydroxy-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-6-heptenoic acid tert-butyl ester 

Downstream Products

• 1352078-35-3 C₂₄H₂₆FNO₃ 

Relevant academic research and scientific papers

Multi-substituted indoles lactone dehydration compound and use thereof

The invention provides a compound, belonging to the field of medicinal chemistry. A structural formula of the compound is described in the specification. According to a test, the compound has the effects of restraining the activity of HMG-coA reductase, and can be used as a new-generation potential HMG-coA reductase inhibitor.

Methods for predicting the response to statins

The invention provides methods for optimizing therapeutic efficacy for treating hypercholesterolemia in a subject having a cardiovascular disease (CVD), comprising (a) determining subject characteristics that affect the likelihood of reaching a goal level of low density lipoprotein (LDL); and (b) obtaining success probabilities of a variety of statin treatments for reaching said goal level of LDL using said subject characteristics and a multivariate model; and (c) administrating the optimal statin treatment with the highest success probability of step (b) to said subject thereby optimizing therapeutic efficacy for treating hypercholesterolemia in said subject.

SUBSTANTIALLY PURE AMORPHOUS FLUVASTATIN, PROCESSES FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME

A process for producing fluvastatin or a pharmaceutically acceptable salt thereof in a substantially pure amorphous form is provided comprising (a) providing a solvent solution comprising substantially non-amorphous fluvastatin or a pharmaceutically accep

Treatment of type 1 diabetes with PDE5 inhibitors

The use of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for the treatment of Type 1 Diabetes. A method of treating Type 1 Diabetes in an individual suffering from Type 1 Diabetes, which method comprises administering to said individual an effective amount of a PDE5 inhibitor without substantial PDE2 inhibiting activity, or a pharmaceutically acceptable salt thereof.

Method for producing pharmaceutical dosage forms

The invention relates to a method for producing a granulate while using spray-dried D-mannitol and to the production of pharmaceutical dosage forms comprised of granulates of this type. The invention additionally relates to granulates obtained by using this method and to pharmaceutical dosage forms, which contain statins, especially cerivastatin, and which can be produced from said granulates.

Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound

A pharmaceutical dosage form comprising an HMG-CoA reductase inhibitor compound, e.g., fluvastatin sodium, is disclosed which is stabilized against pH-related degradation by an alkaline stabilizing medium capable of imparting a pH of at least 8 to an aqueous solution or dispersion of the composition.